Omniox is an biopharmaceutical company developing new medicines for hypoxic diseases. Hypoxia (oxygen deficiency) impacts cancer, cardiovascular diseases, trauma and many other conditions. The firm's developed proprietary oxygen carrier technology (H-NOX) is particularly stable and allows the delivery of oxygen to hypoxic tissue and avoids the failures of prevoius marketed treatments. Omniox's lead candidate, OMX-4.80, is targeting hypoxic cancers including glioblastoma, metastatic brain cancer, head-and-neck cancer, pancreatic cancer, lung cancer, and prostate cancer in combination with standard of care radiation/chemotherapy. Other H-NOX products are being considered for a range of other hypoxic indications including stroke, heart attacks, and trauma.
